Correspondence

Effects of inflammatory bowel disease on in-hospital outcomes in patients with congestive heart failure: A retrospective national inpatient sample study

Dhrubajyoti Bandyopadhyay a, Vardhmaan Jain b, Adrija Hajra c,*, Sandipan Chakraborty d, Raktim K. Ghosh e, Eyal Herzog a

a Mount Sinai St Luke’s Roosevelt Hospital, New York, USA
b Pushpawati Singhania Hospital and Research Institute, New Delhi, India
c IPCMER, SSKM, Kolkata, India
d Interfaith Medical Center, New York, USA
e Case Western Reserve University, Metrohealth, Cleveland, USA

A R T I C L E   I N F O

Article history:
Received 25 February 2019
Accepted 25 March 2019
Available online xxxx

Congestive heart failure (CHF) is defined as a complex clinical syndrome stemming from structural or functional factors that impair ventricular filling or ejection. It is a significant cause of hospitalization, mortality and healthcare expenditure, especially in the aging population. There are around 5 million individuals in the United States with CHF [1]. Inflammatory bowel disease (IBD) is an idiopathic multi-system inflammatory disorder that involves chronic intestinal inflammation interspersed with episodes of flares. The umbrella term mainly describes two main entities- Ulcerative colitis and Crohn’s disease. It’s a global disorder with a prevalence of 0.3% and incidence of 280–320 per 100,000 people in North America [2]. The chronic inflammatory state associated with IBD is a significant risk factor predisposing to a prothrombotic state and increased mortality from coronary artery disease (CAD) as well as CHF [3]. There is a scarcity of literature regarding outcomes of CHF patients with IBD. To our best knowledge, there have been a couple of studies in Denmark and the United States evaluating the incidence of Ischemic Heart Diseases (IHD) in IBD patients [4,5]. There is not much information on long-term outcomes in CHF patients with IBD. We, therefore, undertook this study to evaluate how IBD affected the outcomes in patients admitted for heart failure treatment in an American nationwide cohort.

In this study, we have used the most recent 2016 NIS database. We included all the patients of CHF with and without IBD by using the respective ICD-10 codes. Primary outcomes of interest were mortality, cardiogenic shock, cardiac arrest, stroke, acute kidney injury (AKI), length of stay and cost of care. Multivariate logistic regression was used for adjustment of potential confounders including age, gender, race, socioeconomic status, diabetes, hypertension, smoking, alcohol use, chronic kidney disease, obesity, dyslipidemia, Charlson Comorbidity Index, hospital location, hospital region, teaching status, and hospital size. STATA/IC 15.1 was used for statistical analysis.

In the year 2016, we found 3,053,738 patients admitted for heart failure. Of these patients, 8685 had an established diagnosis of IBD (group A), and 3,045,053 did not have IBD (group B). The mean age in group A was 72.4 years (71.8–73) and that in group B was 72 years (71.8–72.1). Comorbidities like diabetes (20.3%), dyslipidemia (43.8%), obesity (18%), and chronic kidney disease (37.4%) were significantly less common in CHF patients with IBD as compared to those without IBD. The average cost of hospitalization for group A was significantly higher [$84,562 (77,622–91,502), p < 0.05]. The average length of stay was also longer for group A as compared to group B (8.2 vs. 6.4 days) with p-value < 0.05. Upon ethnic consideration, it was found that most patients in group A were white (84.4% vs. 71%). The incidence of AKI was significantly higher in group A as compared to group B in both univariate (OR, 1.25; 95% CI, 1.14–1.4, p value < 0.001) and multivariate analysis (OR, 1.3; 95% CI, 1.16–1.4; p-value < 0.001). There was no difference in mortality, cardiogenic shock, cardiac arrest, and stroke (Table 1).

The elevated levels of inflammatory cytokines in IBD may affect the arterial endothelium. A major contributor for this is the C-reactive protein, which is increased several folds in IBD patients. Among the other inflammatory mediators, tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) also play a significant role in promoting cardiovascular risk. It has been observed that an acute phase reactant calprotectin is elevated in IBD. These mediators lead to arterial damage, chronic ischemic changes of the myocyte and eventually act as an additive factor in the pathogenesis of CHF [6]. Besides CHF, IBD has an important association with other cardiovascular effects. There is a growing body of evidence to show that individuals with IBD are predisposed to ischemic cerebrovascular diseases, atrial fibrillation, peripheral artery disease, venous thrombosis,
and thromboembolic events [7, 8]. Also, IBD flares are associated with increased systemic translocation of bacterial cell wall components that induce tissue (including myocardial) damage and a procoagulant state [3]. Apart from systemic inflammation, increased risk of atherosclerosis and long-term steroid use in IBD play an essential role in the development of CHF in IBD patients [5]. The study involving 736 individuals in Olmsted County, Minnesota, showed that IBD patients had a lower prevalence of cardiovascular risk factors [5]. In our study, we also observed comorbidities like diabetes, dyslipidemia, obesity, and chronic kidney disease were significantly less frequent in CHF patients with IBD as compared to those without IBD. Hence, the increased risk of IHD, as well as CHF in IBD patients, might be contributed by atherosclerosis as a result of chronic systemic inflammation. A Danish study found that there was a 2.5-fold increase in hospitalization rates for CHF in IBD flares [4]. Similarly, the Minnesota study also found that IBD patients were twice as likely to develop HF as compared to controls, and the incidence was correlated with IBD stage [5]. In our study, we also found that IBD patients were at an increased risk for prolonged hospitalization, more resource utilization. We also demonstrated that there was an increased risk of developing AKI in CHF patients who had IBD. Renal involvement, including nephrolithiasis, glomerulonephritis, tubulointerstitial nephritis, and secondary amyloidosis, have been found in 4%-23% of patients with IBD [9]. On the other hand, there are evidences that CHF can predispose to AKI due to decreased cardiac output [10]. The increased number of AKI in group A can be due to CHF itself; otherwise, CHF and IBD both might contribute to the pathogenesis simultaneously. The exact mechanism of increased incidence of AKI in the IBD group requires further studies.

Though this retrospective study based on the administrative database has several limitations including inadequate documentation, coding errors, the absence of patient’s level information, it showed a fascinating influence of IBD on CHF outcomes. It would also make clinicians aware of the anticipated complications.

References
[1] Definition, epidemiology, and risk factors in inflammatory bowel disease - UpToDate [Internet]. [cited 2019 Feb 21]. Available from: https://www.uptodate.com/contents/definition-epidemiology-and-risk-factors-in-inflammatory-bowel-disease.

Table 1
Patients with congestive heart failure (CHF) with and without inflammatory bowel disease (IBD).

| Variables | CHF with IBD (n = 8685) | CHF without IBD (n = 3,045,053) | p value |
|-----------|-------------------------|---------------------------------|--------|
| Mean age  | 72.4 (71.8–73)          | 72 (71.8–72.1)                 | 0.10   |
| Gender (F) | 50.6%                  | 50%                            | 0.70   |
| HTN       | 33%                    | 34.5%                          | 0.22   |
| DM        | 20.3%                  | 30.3%                          | 0.000  |
| Smoking   | 29%                    | 28%                            | 0.37   |
| Dyslipidemia | 43.8%          | 48.3%                          | 0.000  |
| Obesity   | 18%                    | 21.5%                          | 0.000  |
| CKD       | 37.4%                  | 41%                            | 0.003  |
| PAD       | 2.3%                   | 2.6%                           | 0.36   |
| Total charge | 84,562 (77,622–91,502) | 68,071.6 (66,077.8–70,065.4)   | 0.000  |
| Length of stay | 8.2 (7.7–8.7)      | 6.4 (6.3–6.43)                 | 0.000  |
| Race      |                        |                                | 0.000  |
| White     | 84.4%                  | 71%                            |        |
| Black     | 8.6%                   | 17.3%                          |        |
| Hispanic  | 3.5%                   | 7%                             |        |
| Weekend admission | 23%                 | 22.8%                          | 0.90   |
| Bed size  |                        |                                | 0.046  |
| Small     | 15.6%                  | 18%                            |        |
| Medium    | 29.7%                  | 28.5%                          |        |
| Large     | 54.6%                  | 53.3%                          |        |
| Hospital region |                   |                                  | 0.000  |
| North east | 26%                    | 20.4%                          |        |
| Mid-west  | 26.7%                  | 24.3%                          |        |
| South     | 31%                    | 38.3%                          |        |
| West      | 16%                    | 16.4%                          |        |
| Hospital teaching status |              |                                  | 0.000  |
| Rural     | 6.4%                   | 9.4%                           |        |
| Urban non-teaching | 24%             | 25.8%                          |        |
| Urban teaching | 69.4%           | 64.8%                          |        |
| Insurance |                        |                                | 0.000  |
| Medicare | 80%                    | 76%                            |        |
| Medicaid | 4.3%                   | 8.9%                           |        |
| Private including HMO | 12.5%       | 11.3%                          |        |

| Outcomes | Unadjusted odds ratio (OR) | p value | Adjusted odds ratio (OR) | p value |
|----------|----------------------------|---------|--------------------------|---------|
| Mortality| 1.2 (0.97–1.48)            | 0.09    | 1.06 (0.84–1.33)         | 0.61    |
| Cardiogenic shock | 1.03 (0.82–1.3) | 0.76 | 0.89 (0.69–1.14) | 0.36 |
| Cardiac arrest   | 0.85 (0.6–1.2)            | 0.34    | 0.8 (0.56–1.17)         | 0.25    |
| Stroke         | 0.7 (0.45–1.1)            | 0.13    | 0.74 (0.46–1.2)         | 0.20    |
| Acute kidney injury | 1.25 (1.14–1.4) | 0.000 | 1.3 (1.16–1.4) | 0.000 |
| ICU stay       | 1.3 (0.56–3)             | 0.54    | 1.03 (0.4–2.6)          | 0.96    |

| Outcomes | β coefficient (95% CI) | p value |
|----------|------------------------|---------|
| Length of stay | 1.84 (1.4–2.3) | 0.000 |
| Cost of care | 16,490 (9967.2–23,013.4) | 0.000 |

F- female, HTN- hypertension, DM- diabetes, CKD- chronic kidney disease, PAD- peripheral arterial disease, ICU- intensive care unit, HMO- Health Maintenance Organization.
S.C. Ng, H.Y. Shi, N. Hamidi, F.E. Underwood, W. Tang, E.I. Benchimol, R. Panaccione, S. Ghosh, J.C. Wu, F.K. Chan, J.J. Sung. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies, Lancet 390 (10114) (2017 Dec 23) 2769–2778.

S.D. Thapa, H. Hadid, W. Imam, J. Schairer, S.M. Jafri. Effect of Inflammatory Bowel Disease–Related Characteristics and Treatment Interventions on Cardiovascular Disease Incidence, Am. J. Med. Sci. 350 (3) (2015 Sep 1) 175–180.

S.L. Kristensen, O. Ahlehoff, J. Lindhardsen, R. Erichsen, M. Lamberts, U. Khalid, et al., Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study, Circ. Heart Fail. 7 (5) (2014 Sep) 717–722.

S. Aniwan, D.S. Pardi, W.J. Tremaine, E.V. Loftus. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases, Clin. Gastroenterol. Hepatol. 16 (10) (2018 Oct) 1607–1615.e1.

P. Wu, F. Jia, B. Zhang, P. Zhang. Risk of cardiovascular disease in inflammatory bowel disease, Exp. Ther. Med. 13 (2) (2017 Feb 1) 395–400.

Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults - UpToDate [Internet], [cited 2019 Feb 21]. Available from: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults.

S.L. Kristensen, J. Lindhardsen, O. Ahlehoff, R. Erichsen, M. Lamberts, U. Khalid, et al., Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study, Europace 16 (4) (2014 Apr) 477–484.

S. Park, J. Chun, K.D. Han, H. Soh, K. Choi, J.H. Kim, J. Lee, C. Lee, J.P. Im, J.S. Kim. Increased end-stage renal disease risk in patients with inflammatory bowel disease: a nationwide population-based study, World J. Gastroenterol. 24 (42) (2018 Nov 14) 4798.

M. Onuigbo, N. Agbasi, M. Sengodan, K. Rosario. Acute kidney injury in heart failure revisited—the ameliorating impact of “decongestive diuresis” on renal dysfunction in type 1 acute cardiorenal syndrome: accelerated rising Pro B naturetic peptide is a predictor of good renal prognosis, J. Clin. Med. 6 (9) (2017 Aug 29) 82.